Intra-Cellular Therapies (BSP:I2TC34) Total Liabilities : R$735 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Total Liabilities?

Intra-Cellular Therapies's Total Liabilities for the quarter that ended in Mar. 2024 was R$735 Mil.

Intra-Cellular Therapies's quarterly Total Liabilities increased from Sep. 2023 (R$577.74 Mil) to Dec. 2023 (R$670.64 Mil) and increased from Dec. 2023 (R$670.64 Mil) to Mar. 2024 (R$734.71 Mil).

Intra-Cellular Therapies's annual Total Liabilities increased from Dec. 2021 (R$407.33 Mil) to Dec. 2022 (R$517.77 Mil) and increased from Dec. 2022 (R$517.77 Mil) to Dec. 2023 (R$670.64 Mil).

Intra-Cellular Therapies Total Liabilities Historical Data

The historical data trend for Intra-Cellular Therapies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Total Liabilities Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

230.59

311.02

407.33

517.77

670.64

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															492.46	516.98	577.74	670.64	734.71

Intra-Cellular Therapies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Intra-Cellular Therapies's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	605.346	+	(65.295	+	-4.2632564145606E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	671

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3568.5	-	2897.859
	=	671

Intra-Cellular Therapies's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	671.282	+	(63.428	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	735

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3720.09	-	2985.38
	=	735

Intra-Cellular Therapies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (BSP:I2TC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines